Tyler Martin, MD
Dr. Martin is an infectious disease physician who has been working in the biotechnology industry for the past 20 years. He is currently the CEO of Great Plains Biotechnology. In the past he led the project team at Chiron Vaccines (now Novartis) that developed the influenza vaccine adjuvanted with MF59 marketed as FLUAD. Recently, he led the company Dynavax that developed the HBV vaccine adjuvanted with 1018, a TLR9 agonist, currently under review by EMA. He has also led the development of multiple other gene therapy programs, vaccines, and recombinant proteins including monoclonal antibodies.